POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
POINT Biopharma Global Inc. announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President of Business Development, effective January 4, 2022. Dr. Vincent has over 25 years of pharmaceutical business development experience, focusing on partnering and licensing, particularly in Asian markets. He aims to enhance POINT's strategic partnerships and drive the potential of its radiopharmaceuticals in cancer treatment. Previously, he held a senior role at Avacta Life Sciences and brings a strong background in oncology and immuno-oncology.
- Appointment of Matthew Vincent is expected to strengthen business development efforts.
- His experience with global pharmaceutical companies may enhance strategic partnerships.
- Focus on Asian markets could open new revenue opportunities.
- Concerns about continuity in leadership as the company undergoes changes.
Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and autoimmune disease
INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development. Dr. Vincent brings more than 25 years of pharma business development experience through a variety of partnering, licensing, and M&A transactions and will lead licensing activities for POINT, with a focus on expansion into the Asian markets and strategic partnerships to fully realize the potential of POINT’s pan-cancer targeting technologies.
Dr. Vincent’s deal experience includes strategic partnerships and acquisitions involving Pfizer, GSK, BMS, Merck, Genentech/Roche, Moderna and Astellas, as well as several Asian life science companies. Dr. Vincent was most recently Senior Vice President, Business Development at Avacta Life Sciences Ltd., a clinical stage oncology drug company based in London, UK and Boston, MA which develops novel cancer immunotherapies. He earned a Ph.D. in Biochemistry from Tufts University School of Medicine as well as a J.D. from Suffolk University Law School, and he is also a co-inventor on several patents directed to near-clinical drug moieties.
“We are excited to welcome Matt to the POINT leadership team. He brings a deep transactional track record across multiple indications with global pharmaceutical companies,” said Dr. Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma. “We believe that the product candidates in POINT's pipeline are poised to help position radiopharmaceuticals as a new pillar in cancer treatment, with potential across many indications and jurisdictions, as we strive to provide patients globally with a new option in cancer treatment. Matt’s experience in global markets including Asia will help unlock the full potential of our products through new strategic partnerships, creating long term value for POINT.”
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radio-pharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like Actinium-225 and Lutetium-177. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/. Information about POINT Biopharma Global Inc.’s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the benefits of the recently completed business combination, as well as statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the outcome of any legal proceedings that may be instituted against POINT following the closing of the business combination, the risk that the business combination disrupts current plans and operations, the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of POINT to grow and manage growth profitably and retain its key employees, the impact of COVID-19 on POINT’s business, the ability to maintain the listing of POINT’s common stock on the NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in POINT's S-1 registration statement filed with the SEC on July 30, 2021. Most of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Ari Shomair
media@pointbiopharma.com
(647) 812-2417
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
investors@pointbiopharma.com
FAQ
Who is Matthew Vincent, and what is his role at POINT Biopharma?
What experience does Matthew Vincent have in the pharmaceutical industry?
How might Matthew Vincent's appointment impact POINT Biopharma's growth?
When was Matthew Vincent appointed to POINT Biopharma?
